Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today in Law.
Press releases published on June 2, 2025

AeroFlexx Awarded New Patents in Sustainable Packaging Innovation
WEST CHESTER, Ohio, June 02, 2025 (GLOBE NEWSWIRE) -- AeroFlexx, a leader in sustainable packaging, has been awarded U.S. Patents 11,548,709 and 12,071,292. These patents present a flexible plastic package suitable for curbside recycling where all plastic …

Tito’s Handmade Vodka Sponsors RedRover Relief’s Urgent Care Grant Program
Sacramento, California, June 02, 2025 (GLOBE NEWSWIRE) -- For the first time, RedRover® is proud to announce spay and neuter services are now being offered to RedRover Relief Urgent Care grantees as a special “add-on,” thanks to a generous $10,000 …

MSTR REMINDER: Kessler Topaz Meltzer & Check, LLP Urges MSTR Investors with Losses to Contact the Firm
RADNOR, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer …

DEADLINE APPROACHING: Berger Montague Advises BigBear.ai Holdings (NYSE: BBAI) Investors to Inquire About a Securities Fraud Class Action by June 10, 2025
PHILADELPHIA, June 02, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against BigBear.ai Holdings, Inc. (“BigBear” or the “Company”) (NYSE: BBAI) on behalf of purchasers of BigBear …

CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company’s Lead Compound CER-1236
Results in 18 Issued Patents and Allowed Patent Applications Internationally with Nine Total Patent Families SOUTH SAN FRANSCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an …

DP World Deepens Latin America Ties by Joining Regional Port Leadership Body
CHARLOTTE, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- DP World, a global leader in logistics and supply chain solutions, has joined the Inter-American Committee on Ports (CIP) of the Organization of American States (OAS) as an associate member, reinforcing …

CIVI STOCK: Suffer Losses on Civitas Resources, Inc.? BFA Law Notifies Investors of Imminent July 8 Securities Class Action Deadline (NYSE:CIVI)
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti …

ELV STOCK: Suffer Losses on Elevance Health, Inc.? BFA Law Notifies Investors of Imminent July 11 Securities Class Action Deadline (NYSE:ELV)
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti …

IOVA STOCK: Suffer Losses on Iovance Biotherapeutics, Inc.? BFA Law Notifies Investors of Imminent July 14 Securities Class Action Deadline (NASDAQ:IOVA)
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti …

CODI STOCK: Suffer Losses on Compass Diversified Holdings? BFA Law Notifies Investors of Imminent July 8 Securities Class Action Deadline (NYSE:CODI)
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti …

OGN STOCK: Suffer Losses on Organon & Co.? BFA Law Notifies Investors of Imminent July 22 Securities Class Action Deadline (NYSE:OGN)
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti …

URGN STOCK: Suffer Losses on UroGen Pharma Ltd.? BFA Law Notifies Investors of Imminent July 28 Securities Class Action Deadline (NASDAQ:URGN)
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti …

VTRS STOCK DEADLINE TOMORROW: Suffer Losses on Viatris Inc.? BFA Law Notifies Investors of Imminent June 3 Securities Class Action Deadline (NASDAQ:VTRS)
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti …

RDDT STOCK: Suffer Losses on Reddit, Inc.? BFA Law Notifies Investors of Pending Securities Fraud Investigation (NYSE:RDDT)
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti …

U.S. Unmanned Surface Vehicles Market to Hit $362.4 Million by 2028 – Size, Share and Analysis
Delray Beach, FL, June 02, 2025 (GLOBE NEWSWIRE) -- The report "US Unmanned Surface Vehicles Market by Type [Autonomous, Semi-Autonomous], Application (Defense, Commercial), Solution, Cruising Speed, Hull Type, Endurance, Size and Region - Forecasts to …

Exhibit navigating the fight for liberty to open at the Hampton History Museum
Hampton, Virginia, June 02, 2025 (GLOBE NEWSWIRE) -- In commemoration of the 250th Anniversary of the American Revolution, the Hampton History Museum’s newest exhibit explores the story of Hampton during the period. Revolutionary Hampton: Journeys of …

Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
ANN ARBOR, Mich., June 02, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Hetero USA, Inc. and its affiliates Hetero Labs Limited, Hetero Labs Limited Unit-V, and Honour Lab Limited ( …

Aqua Metals Announces Allowance of Foundational U.S. Patent for Lithium Battery Recycling Technology
RENO, Nev., June 02, 2025 (GLOBE NEWSWIRE) -- Aqua Metals, Inc. (NASDAQ: AQMS), a leader in sustainable lithium battery recycling, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent …

Emerita Provides Comments on Announcement Approving Development of Aznalcollar Project, Spain
TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- Emerita Resources Corp. (TSX-V: EMO; OTCQB: EMOTF; FSE: LLJA) (the “Company” or “Emerita”) provides comments with respect to the announcement made on May 30, 2025 by the Minister of Energy and Mines of Andalucia, …

Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist
New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced stages of clinical development in China Phase 2 data suggest potentially similar profile to the only FDA-approved GLP-1/GIP receptor …